Indole-3-carbinol (I3C) and papillomas

What 2 graded rows on indole-3-carbinol (i3c) agree on for papillomas, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Indole-3-carbinol (I3C) page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Indole-3-carbinol (I3C) page, with its PubMed record.

Supplement

Indole-3-carbinol (I3C) Choose another

2 rows · 120 people

They agree: both rows found an improvement.

No difference

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside.

From the rows

The best-graded row, grade D, is an open-label trial of 87 people (2011) and found an improvement.

The rows run from 33 to 87 people, published from 2004 to 2011: 2 single studies.

2 improved

Grade DJuvenile recurrent respiratory papillomatosis · Improved
Open-label trial · n 87 · 2011 · Children aged 2–15 with recurrent respiratory papillomatosis after repeated surgery (Russia)
Not stated in the abstract · 12 weeks to 2 years of use (mean 8.9 months); follow-up 2 to 6.4 years
28.7% had stable remission and 41.1% had 1.5- to 10-fold longer intervals between relapses; 29.9% had no clear effect. No adverse effects were recorded.
Row on the Indole-3-carbinol (I3C) page · PubMed 22334925 (opens PubMed)
Grade DRecurrent respiratory papillomatosis · Improved
Open-label trial · n 33 · 2004 · Adults and children with recurrent respiratory papillomatosis followed a mean 4.8 years after surgery
200 mg twice daily (adults) · Mean 4.8 years follow-up
33% had remission without further surgery, 30% had slower regrowth and 36% had no response; 12 more patients were lost to follow-up. No side effects attributed to I3C were found.
Row on the Indole-3-carbinol (I3C) page · PubMed 15193659 (opens PubMed)